{"id":"https://openalex.org/W4386535898","doi":"https://doi.org/10.17116/medtech20234503170","title":"Cost-effectiveness and budget impact analysis of fixed combination of alogliptin and pioglitazone in the treatment of type 2 diabetes mellitus","display_name":"Cost-effectiveness and budget impact analysis of fixed combination of alogliptin and pioglitazone in the treatment of type 2 diabetes mellitus","alternate_titles":[],"publication_year":2023,"publication_date":"2023-09-08","ids":{"openalex":"https://openalex.org/W4386535898","doi":"https://doi.org/10.17116/medtech20234503170"},"language":"en","primary_location":{"id":"doi:10.17116/medtech20234503170","doi":"https://doi.org/10.17116/medtech20234503170","is_oa":true,"landing_page_url":"https://doi.org/10.17116/medtech20234503170","pdf_url":null,"source":{"id":"https://openalex.org/S4210174297","display_name":"Medical Technologies Assessment and Choice","issn_l":"2219-0678","issn":["2219-0678","2712-7877"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20","russia-white-list-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medical Technologies. Assessment and Choice","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4386535898"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.17116/medtech20234503170","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050351339","display_name":"\u042e\u043b\u0438\u044f \u0412\u0438\u0442\u0430\u043b\u044c\u0435\u0432\u043d\u0430 \u0421\u0442\u0440\u0443\u043d\u0438\u043d\u0430","orcid":"https://orcid.org/0000-0002-6751-2903","observed_orcids":["https://orcid.org/0000-0002-6751-2903"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yu.V. Strunina","raw_affiliation_strings":["Association of Specialists in Health Technology Assessment, Moscow, Russia"],"raw_orcid":"https://orcid.org/0000-0002-6751-2903","affiliations":[{"raw_affiliation_string":"Association of Specialists in Health Technology Assessment, Moscow, Russia","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001973905","display_name":"Nina Alexandrovna Petunina","orcid":"https://orcid.org/0000-0001-9390-1200","observed_orcids":["https://orcid.org/0000-0001-9390-1200"]},"institutions":[{"id":"https://openalex.org/I17877952","display_name":"Sechenov University","ror":"https://ror.org/02yqqv993","country_code":"RU","type":"education","lineage":["https://openalex.org/I17877952"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"N.A. Petunina","raw_affiliation_strings":["Sechenov First Moscow State Medical University, Moscow, Russia"],"raw_orcid":"https://orcid.org/0000-0001-9390-1200","affiliations":[{"raw_affiliation_string":"Sechenov First Moscow State Medical University, Moscow, Russia","institution_ids":["https://openalex.org/I17877952"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1503,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.38857437,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"45","issue":"3","first_page":"70","last_page":"70"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.6205999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.6205999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.36649999022483826,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.005799999926239252,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alogliptin","display_name":"alogliptin","score":0.9240000247955322},{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":1.0},{"id":"https://openalex.org/keywords/fixed-dose-combination","display_name":"fixed-dose combination","score":0.7900000214576721},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9959999918937683},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8240000009536743},{"id":"https://openalex.org/keywords/budget-impact-analysis","display_name":"budget impact analysis","score":0.8640000224113464},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.9399999976158142},{"id":"https://openalex.org/keywords/glibenclamide","display_name":"glibenclamide","score":0.9679999947547913},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.7369999885559082},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.9520000219345093},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.42800000309944153},{"id":"https://openalex.org/keywords/russian-healthcare-system","display_name":"Russian healthcare system","score":0.4259999990463257}],"concepts":[{"id":"https://openalex.org/C2780012697","wikidata":"https://www.wikidata.org/wiki/Q4734170","display_name":"Alogliptin","level":5,"score":0.9745727777481079},{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.9473340511322021},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.578616738319397},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.48370200395584106},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.46716344356536865},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44928669929504395},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4157130718231201},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.32509899139404297},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.15461769700050354},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.17116/medtech20234503170","doi":"https://doi.org/10.17116/medtech20234503170","is_oa":true,"landing_page_url":"https://doi.org/10.17116/medtech20234503170","pdf_url":null,"source":{"id":"https://openalex.org/S4210174297","display_name":"Medical Technologies Assessment and Choice","issn_l":"2219-0678","issn":["2219-0678","2712-7877"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20","russia-white-list-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medical Technologies. Assessment and Choice","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.17116/medtech20234503170","doi":"https://doi.org/10.17116/medtech20234503170","is_oa":true,"landing_page_url":"https://doi.org/10.17116/medtech20234503170","pdf_url":null,"source":{"id":"https://openalex.org/S4210174297","display_name":"Medical Technologies Assessment and Choice","issn_l":"2219-0678","issn":["2219-0678","2712-7877"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20","russia-white-list-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medical Technologies. Assessment and Choice","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W71678318","https://openalex.org/W1997416444","https://openalex.org/W2008497553","https://openalex.org/W2027788348","https://openalex.org/W2059439623","https://openalex.org/W2064617441","https://openalex.org/W2086842286","https://openalex.org/W2089437710","https://openalex.org/W2104288577","https://openalex.org/W2121970519","https://openalex.org/W2127854619","https://openalex.org/W2151668968","https://openalex.org/W2163498104","https://openalex.org/W2288961493","https://openalex.org/W2889064714","https://openalex.org/W2913840884","https://openalex.org/W2963830642","https://openalex.org/W4283156641","https://openalex.org/W4294163402","https://openalex.org/W6963698426"],"related_works":["https://openalex.org/W4407809082","https://openalex.org/W2114916977","https://openalex.org/W6963698426","https://openalex.org/W2806725895","https://openalex.org/W2559909899","https://openalex.org/W4405510646","https://openalex.org/W3214572786","https://openalex.org/W2096430659","https://openalex.org/W2544388418","https://openalex.org/W2352870259"],"abstract_inverted_index":{"Objective.":[0],"To":[1],"determine":[2],"the":[3,22,40,191],"optimal":[4],"therapy":[5],"regarding":[6],"cost-effectiveness":[7,74,155],"and":[8,19,33,71,73,88,101,124],"budget":[9,96],"impact":[10,97],"analysis":[11,57,75,98],"of":[12,17,24,43,68,86,121,127,144,158,176],"fixed":[13],"drug":[14,48],"combination":[15,67,85,120,143,175],"(FDC)":[16],"alogliptin":[18,87,107,129,145,160,177,185],"pioglitazone":[20,63,81,109,164,187],"in":[21,52,95],"treatment":[23,114],"adults":[25],"with":[26,45,64,82,110,135,146,167,178,188,215],"diabetes":[27],"mellitus":[28],"(DM)":[29],"type":[30],"2.":[31],"Material":[32],"methods.":[34],"Statistical":[35],"data":[36],"were":[37,50],"obtained":[38],"from":[39],"federal":[41],"register":[42],"patients":[44],"DM.":[46],"Only":[47],"costs":[49],"considered":[51],"study.":[53],"We":[54],"used":[55],"cost-minimization":[56],"for":[58,76,99,208],"scenario":[59,77],"1":[60],"(alogliptin":[61,79],"+":[62,80,108,163,186],"metformin":[65,83,111,136,147,168,189,216],"vs.":[66,84],"alogliptin,":[69,122],"glibenclamide":[70,123],"metformin)":[72],"2":[78],"metformin).":[89],"Time":[90],"horizon":[91],"was":[92,137,151,169],"3":[93,201],"years":[94,202],"current":[100,205],"simulated":[102,181],"clinical":[103,149,182,206],"practice.":[104],"Results.":[105],"FDC":[106,128,159,184,213],"reduced":[112],"annual":[113],"cost":[115,192],"by":[116,139,171,193,198],"0.4%":[117],"compared":[118,141,173,203,224],"to":[119,142,174,204],"metformin.":[125,179],"Cost":[126],"25":[130,161],"mg":[131,134,162,166],"+pioglitazone":[132],"15":[133],"lower":[138,170],"15.2%":[140],"while":[148],"effectiveness":[150],"higher.":[152],"The":[153],"incremental":[154],"ratio":[156],"(ICER)":[157],"30":[165],"62.5%":[172],"In":[180],"practice,":[183],"reduce":[190],"731.6":[194],"million":[195],"rubles":[196],"(lower":[197],"10.7%)":[199],"throughout":[200],"practice":[207],"109":[209],"768":[210],"patients.":[211],"Conclusion.":[212],"alogliptin+pioglitazone":[214],"is":[217],"either":[218],"cost-effective":[219],"or":[220],"cost-caving":[221],"option":[222],"vs":[223],"alternatives.":[225]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4386535898","counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2023-09-09T00:00:00"}
